Nasdaq · Healthcare
HARVARD BIOSCIENCE INC (HBIO)
As-reported financials and recent SEC filings for HARVARD BIOSCIENCE INC, latest fiscal period FY2025. Every figure is pulled straight from the company’s EDGAR filings — no estimates.
Snapshot
Revenue
$86.5M
Net income
$-56.7M
Net margin
-65.5%
Diluted EPS
$-1.28
ROE
-412.8%
P/E (TTM)
—
Market cap
—
Debt / equity
2.6×
Income statement (as reported)
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $86.5M | $94.1M | $112.3M | $113.3M | $118.9M |
| Gross profit | $49.9M | $54.8M | $66.1M | $60.8M | $67.7M |
| Operating income | $-48.6M | $-6.2M | $1.9M | $-6.9M | $2.1M |
| Net income | $-56.7M | $-12.4M | $-3.4M | $-9.5M | $-288,000 |
| Diluted EPS | $-1.28 | $-0.28 | $-0.08 | $-0.23 | — |
Source: company XBRL financial statements on SEC EDGAR.
Recent SEC filings
42026-06-12
View on EDGAR →42026-06-11
View on EDGAR →42026-06-11
View on EDGAR →42026-06-11
View on EDGAR →42026-06-11
View on EDGAR →S-82026-06-10
View on EDGAR →8-K2026-06-02
View on EDGAR →SD2026-05-27
View on EDGAR →Largest Healthcare peers
Go deeper on HBIO
Search HARVARD BIOSCIENCE INC’s filings with cited answers, compare it against peers, build an operating model, and track it in your portfolio — all in one place.
Start freeOr check your whole portfolio free — no account needed.
Data sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only — not investment advice.